证券代码：300391 证券简称：*ST长药 编号：2025-057 长江医药控股股份有限公司 2024年度股东会决议公告 1、本次股东会无增加、变更、否决提案的情况； 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 特别提示： 2、本次股东会以现场投票表决和网络投票表决的方式召开。 一、会议召开和出席情况 1、召集人：公司董事会 2、召开方式：现场投票与网络投票相结合的方式 3、召开时间： （1）现场会议时间：2025 年 5 月 13 日（星期二）下午 15:30 6、会议主持人：公司董事长王波先生。 7、会议出席情况： （1）出席会议的总体情况 参加会议的股东（代理人）共 91 名，所持（代理）股份 38,821,200 股，占 1 （2）网络投票时间：2025 年 5 月 13 日。其中，通过深圳证券交易所交易 系统进行网络投票的时间为 2025 年 5 月 13 日上午 9:15-9:25，9:30-11:30， 下午 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为 2025 年 5 月 13 日 9:15-15:00。 4、 ...

湖北英达律师事务所 关于长江医药控股股份有限公司 2024 年年度股东大会的 法律意见书 中国武汉市新华路 186 号福星国际商会大厦 18 楼 电话：86.27.85350032 传真：86.27.85350997 邮政编码：430022 网址:www.yingdalaw.com 二○二五年五月 英达律师事务所 法律意见书 湖北英达律师事务所 关于长江医药控股股份有限公司 2024 年年度股东大会的 法律意见书 致：长江医药控股股份有限公司 湖北英达律师事务所（下称"本所"）接受长江医药控股股份有限公司（下称 "公司"）委托，指派本所律师宋浩、周凌雷现场见证公司于 2025 年 5 月 13 日 召开的 2024 年年度股东大会（以下简称"本次股东大会"），并根据《中华人民 共和国公司法》（下称"《公司法》"）、《中华人民共和国证券法》（下称"《证 券法》"）、中国证券监督管理委员会发布的《上市公司股东大会规则》（下称 "《股东大会规则》"）等相关法律、法规、规范性文件以及《长江医药控股股份 有限公司章程》（下称"《公司章程》"）的有关规定，就本次股东大会的召集和 召开程序、出席会议人员的资格和召集人资格、 ...

Group 1: New Stock Offerings - ST Xinchao (600777) has a tender offer period from April 23, 2025, to May 22, 2025[1] - Puli Tui (300630) has 7 trading days remaining until the last trading day[1] - ST Zhongcheng (300208) reported severe abnormal fluctuations[1] Group 2: Trading Alerts - Jintai (300225) and other stocks are under observation for trading alerts due to abnormal fluctuations[1] - ST Yida (600608) and ST Huke (600608) are also flagged for trading alerts[1] - Multiple stocks including ST Shengda (002259) and ST Yushun (002289) are under scrutiny for trading activities[1] Group 3: Recent Announcements - Guofang Group (601086) and other companies have made recent announcements regarding their stock activities[1] - A total of 7 trading days remain for several stocks approaching their last trading day[1] - Various companies including ST Huada (603580) and ST Aiai (603580) have made recent disclosures[1]

Group 1: Company Restructuring and Financial Status - The company signed a restructuring investment agreement on May 6, 2025, and the pre-restructuring work is progressing in an orderly manner [1] - The audited net assets attributable to the parent company for 2024 are negative, posing a risk of stock delisting [2] - If the restructuring is successful, it will significantly improve the company's financial status and reduce debt [3] Group 2: Stock Increase and Capital Structure - The company plans to increase its capital by converting 10 shares into 15 shares, resulting in a total share capital increase from 350,336,112 shares to 875,840,280 shares [2] - The conversion price is set at 2.42 CNY per share, with a total of 525,504,168 shares available for conversion [2] - Remaining shares after the restructuring will be used to repay ordinary creditors at a price not lower than 10 CNY per share [2] Group 3: Investor Relations and Market Concerns - The company is addressing investor concerns regarding stock price fluctuations influenced by various factors, including company performance and market conditions [2] - There is no current request from industry investors to change the company's main business [2] - The company has not received any consent letters from the China Securities Regulatory Commission regarding the restructuring [3] Group 4: Management and Operational Changes - If the restructuring is successful, the controlling shareholder will change to Sichuan Jiadaobowen Ecological Technology Co., Ltd. [3] - The new industry investors are expected to recommend talent to enhance the company's operational capabilities [4] - The company currently has no specific plans for its photovoltaic sector [3]

Core Points - The Shanghai Composite Index is at 3343.28 points, slightly down by 0.26%, with a total trading volume of 590.62 billion yuan [1] - 24 A-shares have surpassed their annual moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Huaihe Energy (600575) has the highest deviation rate at 9.45%, with a daily increase of 10.03% and a turnover rate of 4.61% [2] - *ST Changyao (300391) follows with a deviation rate of 3.71%, increasing by 4.37% today [2] - Shuiyang Co., Ltd. (300740) shows a deviation rate of 3.58% with an 8.70% increase [2] Other Notable Stocks - *ST Chuangxing (600193) has a deviation rate of 3.47% and a daily increase of 4.94% [2] - Yahua Electronics (301337) has a deviation rate of 3.40% with a 5.06% increase [2] - Shaanxi Huada (301517) shows a 4.25% increase and a deviation rate of 3.38% [2] Market Overview - The overall A-share market is experiencing fluctuations, with a total trading volume of 590.62 billion yuan, indicating active trading [1]

Core Viewpoint - *ST Changyao has made significant progress in its restructuring process, with the main investor, Jia Dao Bowan, set to become the controlling shareholder after a capital increase and share transfer agreement [1][2][6]. Company Summary - *ST Changyao primarily engages in the production and sale of traditional Chinese medicine pieces, as well as the wholesale of pharmaceuticals, health products, and medical devices [2]. - The company initiated pre-restructuring in January, and after over three months, it signed restructuring investment agreements with six investors, including Jia Dao Bowan and other financial investors [2][6]. - The restructuring plan involves a capital increase of approximately 526 million shares, with Jia Dao Bowan investing 593 million yuan to acquire 245 million shares at a price of 2.42 yuan per share [2][6]. Financial Performance - In 2024, *ST Changyao reported a net profit loss of 628 million yuan, with revenue plummeting from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [6]. - The company faces significant financial distress, including overdue debts and lawsuits from creditors, leading to frozen bank accounts and asset seizures [6]. Investor Background - Jia Dao Bowan, controlled by Gong Hongjia and Chen Chunmei, is the second-largest shareholder of Hikvision and has a strong background in investment, particularly in the security sector [1][5]. - Gong Hongjia has committed to providing up to 1 billion yuan to support *ST Changyao's restructuring and operational needs [5]. Strategic Implications - The acquisition of controlling interest in *ST Changyao marks a shift in Jia Dao Bowan's investment strategy from purely financial investments to seeking operational control [7]. - The investment aligns with Jia Dao Bowan's existing business in ecological agriculture, which may synergize with *ST Changyao's traditional medicine operations [7]. Industry Context - The restructuring of *ST Changyao is part of a broader trend in the pharmaceutical industry, where companies are seeking to revitalize through mergers and acquisitions amid changing market dynamics [8]. - Other companies in Hubei, such as Renfu Pharmaceutical and *ST Meigu, are also undergoing restructuring, indicating a potential shift in investment focus towards revitalizing distressed assets in the healthcare sector [8].

Core Viewpoint - A company involved in "gutter oil" processing has emerged as an investor in the restructuring of *ST Changyao, indicating a significant shift in the company's ownership and potential future direction [1][4]. Investment and Financial Structure - *ST Changyao has signed restructuring investment agreements with two industrial investors, Sichuan Jiadaobowen Ecological Technology Co., Ltd. and Haowei Biological, with plans to increase its total share capital from 350 million shares to 876 million shares through a capital reserve transfer [3][4]. - Jiadaobowen will pay 593 million yuan to acquire 245 million shares of *ST Changyao, becoming the controlling shareholder post-restructuring [4]. Background of Investors - Jiadaobowen is backed by prominent capital figures Gong Hongjia and Chen Chunmei, who control 97.95% of the company [5][6]. - Jiadaobowen's total assets are reported at 1.22 billion yuan, with a net asset of 650 million yuan, and it recorded a revenue of 176 million yuan with a net loss of 16.09 million yuan in 2024 [5]. Historical Context and Market Activity - Gong Hongjia has a notable history in the capital market, having founded several successful companies and achieved significant investment returns, including a 20,000-fold return from an investment in Hikvision [7][10]. - The couple has been active in the A-share market, previously investing in companies like Tianxiang Environment and *ST Kaiyuan, demonstrating a pattern of engaging in restructuring opportunities [11][14]. Current Challenges - *ST Changyao is currently facing difficulties, with its 2024 financial report receiving a non-standard opinion from auditors, indicating a heavy burden for the company to maintain its listing status in 2025 [12].

备受资本市场关注的*ST长药（300391）（300391.SZ）重整事宜，迎来新进展。5月8日，*ST长药发布 公告称，2025年5月6日，公司和临时管理人分别与产业投资人四川嘉道博文生态科技有限公司等六家机 构签署重整投资协议。 *ST长药方面表示，若公司预重整及重整程序得以顺利推进并重整成功，将有利于改善公司的财务结 构、化解债务。在引入重整投资人后，公司可获得增量资金，有利于恢复和增强公司的持续经营能力。 六家机构携手投资入局 2025年1月20日，*ST长药收到湖北省十堰市中级人民法院（下称"十堰中院"）送达的《决定书》，十 堰中院决定对公司启动预重整，并指定上海市锦天城律师事务所担任公司预重整期间的临时管理人。 公告披露，经*ST长药临时管理人组织召开遴选委员会会议，由遴选委员会对意向投资人提交的重整投 资方案进行评审，最终投票确定了磋商谈判重整投资协议的顺位。经与排序优先的候选投资人进行磋商 后，2025年5月6日，公司和临时管理人分别与产业投资人四川嘉道博文生态科技有限公司、十堰市昊炜 生物科技发展有限公司，财务投资人合肥当歌长弘创业投资合伙企业(有限合伙)、安徽宏业股权投资基 金有限公司、上 ...

特别风险提示： 证券代码：300391 证券简称：长药控股 公告编号：2025-055 长江医药控股股份有限公司 关于签署重整投资协议暨关联交易的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 经公司临时管理人组织召开遴选委员会会议，由遴选委员会对意向投资人提交 的重整投资方案进行评审，最终投票确定了磋商谈判重整投资协议的顺位。经与排 序优先的候选投资人进行磋商后，2025 年 5 月 6 日，公司和临时管理人分别与产业 投资人四川嘉道博文生态科技有限公司、十堰市昊炜生物科技发展有限公司，财务 投资人合肥当歌长弘创业投资合伙企业(有限合伙)、安徽宏业股权投资基金有限公 司、上海琉光东承企业管理咨询合伙企业（有限合伙）、大涵私募证券基金管理（深 圳）有限公司签署重整投资协议。 关于本次重整投资协议，可能存在因重整投资人筹措资金不到位等无法按照协 议约定履行投资义务的风险。虽然《重整投资协议》已经签署，但仍可能存在签署 补充协议、协议被终止、解除、撤销、认定为未生效、无效或不能履行等风险。 敬请广大投资者注意投资风险，理性投资。 一、公司预重整情况及关联交易概 ...

证券代码：300391 证券简称：长药控股 公告编号：2025-056 长江医药控股股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、本次股东大会召开的基本情况 1、股东大会届次：2025年第二次临时股东大会 2、股东大会召集人：本次股东大会的召集人为董事会 3、会议召开的合法、合规性：公司第五届董事会第二十五次会议审议通过了 《关于召开2025年第二次临时股东大会的议案》，召集程序符合有关法律、行政 法规、部门规章、规范性文件和公司《章程》的规定。 4、会议召开时间： 现场会议时间：2025年5月23日（星期五）下午15:30 网络投票时间：2025年5月23日。其中，通过深圳证券交易所交易系统进行网 络投票的时间为2025年5月23日上午9:15-9:25，9:30-11:30，下午13:00-15:00； 通过深圳证券交易所互联网系统投票的具体时间为2025年5月23日9:15-15:00。 5、会议召开方式：现场投票与网络投票相结合的方式。 现场投票：股东本人出席现场会议或者通过授权委托书（见 ...